Contents

Preface vii Contributors viii Acknowledgment xi

Part 1 Introduction

- **1** Milestones in neonatology 2
- 2 Epidemiology 4

Part 2 Perinatal medicine

- **3** Perinatal medicine overview 6
- 4 Prepregnancy care, prenatal screening, and fetal medicine 8
- **5** Maternal medical conditions 10
- **6** Intrauterine growth restriction 12
- 7 Multiple births 14
- 8 Preterm delivery 16
- 9 Maternal drugs affecting the fetus and newborn infant 18
- **10** Congenital infection 20
- **11** Genetics 24

Part 3 Delivery

- **12** Adaption to extra-uterine life 28
- **13** Neonatal resuscitation and post-resuscitation care 30
- 14 Birth injuries 38

Part 4 The newborn infant

- **15** Routine care of the newborn infant 40
- **16** Routine examination of the newborn infant 42
- 17 Neurology examination 44
- 18 Feeding 46
- **19** Parental attachment 48
- 20 Minor abnormalities in the first few days 50
- 21 Overview of common problems of term infants 52

Part 5 Neonatal unit admission

- **22** Admission to the neonatal unit 54
- **23** Stabilizing the sick newborn infant 56
- 24 Respiratory support 60
- **25** Developmental care 66
- **26** Family integrated care 68

Part 6 The preterm infant

- **27** Preterm infants and their complications 70
- **28** Lung development and surfactant 72
- **29** Respiratory distress syndrome 74
- **30** Temperature control 76
- **31** Growth and nutrition 78
- **32** Intraventricular hemorrhage and periventricular leukomalacia 82
- 33 Patent ductus arteriosus (PDA) 84
- 34 Apnea, infection, anemia, and jaundice 86
- **35** Retinopathy of prematurity 88
- **36** Necrotizing enterocolitis 90
- **37** Bronchopulmonary dysplasia 92
- **38** Discharge of preterm infants from hospital 94
- **39** Outcome of preterm infants 96

Part 7 Neonatal problems

- **40** Respiratory distress in term infants 100
- 41 Upper airway disorders 104
- **42** Jaundice 106
- 43 Neonatal infection 110
- 44 Antimicrobial stewardship 112
- **45** Specific bacterial infections 114
- **46** Viral infections 116
- 47 Hypoglycemia and hyperglycemia 118
- **48** Gastrointestinal disorders 120
- **49** Gastrointestinal obstruction 124
- **50** Cardiac disorders 126
- **51** Hypoxic–ischemic encephalopathy 132
- 52 Seizures and perinatal strokes 136
- **53** Neural tube defects and hydrocephalus 138
- **54** The hypotonic infant 140
- **55** Renal and urinary tract anomalies diagnosed prenatally 142
- **56** Renal and urinary tract disorders 144
- **57** Genital disorders 148
- **58** Disorders of sex development 150
- **59** Anemia and polycythemia 152
- **60** White cell disorders 154
- **61** Coagulation and thrombotic disorders 156
- **62** Dermatological disorders 160
- **63** Bone and joint disorders 162
- **64** Inborn errors of metabolism 164
- **65** Hearing and vision 166

Part 8 Aspects of neonatal intensive care

- **66** Pain 168
- 67 Pharmacology 170
- **68** Quality improvement 172
- 69 Patient safety 174
- **70** Evidence-based practice 180
- **71** Ethics 182
- 72 Research and consent 186
- **73** Palliative and end-of-life care 188

Part 9 Follow-up

74 Follow-up of high-risk infants 190

Part 10 Global

75 Global neonatology 192

Part 11 Transport

76 Transport of the sick newborn infant 196

Part 12 Practical procedures

- 77 Intubation 198
- **78** Chest tubes 200
- **79** Common practical procedures 202
- **80** Umbilical catheters and intraosseous cannulation 204
- 81 Central venous catheters and exchange transfusions 206
- 82 Cranial ultrasound 208
- **83** Brain monitoring 212
- 84 Perinatal neuroimaging with MRI 216
- **85** Echocardiography for the neonatologist 218

Appendix: Gestational age assessment, BP, Newborn Early Warning Trigger and Track (NEWTT) chart, Jaundice, Hypoglycemia, Growth charts 222

Further reading 230

Index 234



1 Milestones in neonatology

The care of newborn infants has evolved over the last century from simple and empirical care to modern, evidence-based, high-tech medicine. Neonatal mortality has correspondingly declined dramatically from 40/1000 live births in 1900 to <4/1000 in the US and UK. Improved obstetric care and maternal health and nutrition have also contributed. It was only in the 1950s that medical care of healthy and sick newborn infants was transferred from obstetricians to pediatricians. The specialty of neonatology developed only in the 1960s, and the first certifying examination for physicians in the US was held in 1975.

Thermal regulation

• 1890s: Tarnier in France showed that a warm, controlled environment reduced mortality of infants <2 kg from 66% to 38% (Figure 1.1).

• 1893: Budin, Tarnier's student, established the first unit for premature babies in Paris, emphasizing thermal regulation and breast-feeding.

• Early 1900s: Premature babies in incubators were exhibited in fairs around Europe and the US (Figure 1.2).


• 1950s: Silverman in the US conducted elegant randomized controlled trials to confirm the beneficial effects of thermal control (including humidity) on mortality.


• 2000s: Heat loss at delivery of extremely preterm babies minimized by plastic wrapping.

Nutrition

• 1880s: Tarnier and Budin recommend early feeding and intragastric "gavage" feeding via a rubber tube inserted through the mouth.

• 1907: Rotch in US introduces infant formula. Breast-feeding declines as some believed formula was superior.








Figure 1.2 Incubators with premature babies at the Pan-American Exposition, Buffalo, New York in 1901. Source: Silverman WA. Incubator-baby side shows. *Pediatrics* 1979; **64**: 127. Courtesy of the American Academy of Pediatrics.

• 1940s: Gavage feeding via a nasogastric tube used in neonatal units.

• 1940s: Feeding of preterm infants delayed up to four days to avoid aspiration. Adverse effects (hypoglycemia, increased bilirubin and impaired development) recognized only in the 1960s, and early feeding reintroduced.

• 1960s: Parenteral nutrition (PN) introduced by central venous catheter, then via peripherally inserted central catheters (PICC) lines.

• 1960s: Infant formula associated with neonatal tetany from hypocalcemia and hemolysis from vitamin E deficiency.

• 1980s: Development of special formulas for very low birthweight infants.

• 1980s: Resurgence of use of breast milk. Human milk fortifiers developed for preterm infants.

• 2000s: Addition of long-chain polyunsaturated fatty acids (LCPUFA) to formula.

Rhesus hemolytic disease

Kernicterus, from bilirubin deposition in the brain in rhesus disease, was first described in 1938. Exchange transfusions became a common procedure in neonatal units and saved an estimated 8000 lives/year in the US alone.

• 1925: Hart describes first exchange transfusion – blood given via saphenous vein, removed from anterior fontanelle.

• 1940: Landsteiner discovers rhesus factor.

• 1945: Coombs develops Coombs test (direct antiglobulin test [DAT]) to detect rhesus agglutinins.

• 1947: Diamond describes exchange transfusion via umbilical vein with rubber catheter.

- 1963: Liley introduces intrauterine transfusion.
- 1964: Freda and Clarke develop prophylaxis with anti-D immunoglobulin.
- 1968: Rho(D) immune globulin prophylaxis introduced. Rhesus disease now almost completely prevented in high income countries.

Neonatology at a Glance, Fourth Edition. Edited by Tom Lissauer, Avroy A. Fanaroff, Lawrence Miall and Jonathan Fanaroff. © 2020 John Wiley & Sons Ltd. Published 2020 by John Wiley & Sons Ltd.

Antibiotics

Before antibiotics, mortality from neonatal sepsis was almost 100%, but it declined markedly when penicillin was introduced in 1944. The organisms causing sepsis have changed (Figure 1.3).

Respiratory distress syndrome (RDS)

History of respiratory distress syndrome (surfactant deficiency)

• 1955: Pattle describes properties of surfactant.

• 1956: Clements isolates surfactant.

• 1959: Avery and Mead demonstrate lack of surfactant in preterm lungs.

• 1972: Liggins and Howie show that prenatal corticosteroids to the mother induce fetal lung maturity.

• 1980: Fujiwara – first surfactant replacement therapy.

• 1985: Multicenter clinical trials of natural and artificial surfactant replacement therapy.

• 1989: Surfactant therapy approved.

Oxygen therapy, monitoring, and respiratory support

Whereas about 25000 infants died every year in the US from respiratory distress syndrome (RDS) in the early 1950s, by 2003 there were fewer than 500 such deaths.

This has resulted from:

• Understanding the pathogenesis of RDS, which enabled development of surfactant replacement therapy.

• Antenatal corticosteroids to induce surfactant and lung maturation.

• Developments in respiratory support:

- oxygen therapy.

- continuous positive airway pressure (CPAP), introduced by Gregory.

 mechanical ventilators, first shown to improve survival by Swyer in Toronto and Reynolds in London (1965).

- · Ability to closely monitor vital signs and blood gases:
 - cardiorespiratory monitors for neonates
 - measurement of blood gases on small blood samples
 - umbilical/peripheral artery catheters
 - non-invasive oxygen saturation monitors.

• 2010s: increasing use of non-invasive respiratory support to avoid or reduce mechanical ventilation.

Key point

Since the 1950s RDS has been a major focus of research in neonatology. Understanding its pathophysiology and the biochemistry of surfactant has been the key to developing surfactant therapy and respiratory support, which have dramatically improved survival.




Figure 1.3 Change with time of main organisms causing neonatal infection.

Development of neonatal intensive care

• 1922: First neonatal unit in US in Chicago by Hess; in UK by Crosse in Birmingham in 1945.

• 1960s and 1970s: Development of regional neonatal intensive care units with dedicated staff, introduction of CPAP and mechanical ventilation.

- 1970s: Ultrasound to identify intraventricular hemorrhage.
- 1970s: Ability to safely perform surgery in tiny infants.
- 1980s: Development of multicenter clinical trials, national, and international.
- 1980s: Extracorporeal membrane oxygenation (ECMO).
- 1990s: Nitric oxide (NO) therapy for persistent pulmonary hypertension of the newborn.
- 2000s: Mild hypothermia shown to reduce morbidity of hypoxicischemic encephalopathy.
- 2010s: Non-invasive prenatal testing (NIPT) free fetal DNA analysis from maternal blood for Trisomy 21 etc.

Whole genome sequencing for critically ill newborns

Challenges for the future

• Reduce prematurity, hypoxic-ischemic brain injury, neonatal infection, congenital abnormalities.

• Prevent complications of prematurity: brain injury, necrotizing enterocolitis, bronchopulmonary dysplasia, retinopathy of prematurity.

- Practice evidence-based medicine.
- Improve patient safety reduce medication errors etc.
- · Develop better non-invasive monitoring.
- Enhance nursery environment and parental satisfaction.
- Confront ethical dilemmas at the limit of viability and withdrawal of life support.
- Improve/extend care at home of technology-dependent infants.
- Develop personalized medicine incorporating modern genetics.
- Global reduction of neonatal mortality (2.5 million in 2018).